(Q38236623)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

Vandetanib as a potential treatment for breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Nicola Normanno

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Antonella De Luca

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Marianna Gallo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

2

Amelia D'Alessio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Monica Rosaria Maiello

3

object named as

Monica Rosaria Maiello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

5

Simona Bevilacqua

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

6

Daniela Frezzetti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Francesco Perrone

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

language of work or name

English

0 references

publication date

4 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

11 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

1295-1303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25089348%20AND%20SRC:MED&resulttype=core&format=json

Target-based therapies in breast cancer: current status and future perspectives.

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Role of epidermal growth factor receptor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

An overview of small-molecule inhibitors of VEGFR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

The role of antiangiogenetic agents in the treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Vandetanib: An overview of its clinical development in NSCLC and other tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Combining antiangiogenics to overcome resistance: rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942034